Biomea Fusion Inc宣布,其在研药物Icovamenib在第52周的临床试验中取得积极进展,B组患者的糖化血红蛋白(HbA1c)较安慰剂组平均降低1.8%。
Biomea Fusion Inc宣布,其在研药物Icovamenib在第52周的临床试验中取得积极进展,B组患者的糖化血红蛋白(HbA1c)较安慰剂组平均降低1.8%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.